Pharma News

On the eve of World AIDS Day, Cipla Ltd., a global pharmaceutical company, announced its readiness to supply its combinations Tenofovir/Emtricitabine/Efavirenz and Tenofovir/ Lamivudine /Efavirenz with a dose of 400 mg of Efavirenz as a first-line initial therapy for HIV infection.

Aurobindo Pharma said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.

AbbVie, is introducing Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long condition of hypothyroidism. When and how patients take their medication can affect the way the body absorbs it so resources encouraging patients to establish and follow to their a daily routine are important. The goal of the new website is to help patients better manage their hypothyroidism by establishing a daily routine, spirit of connection, and a sense of community through tools and resources such as a patient journal, medication refill reminder and a network of hypothyroidism patients.

China is expected to have over 800,000 lung cancer patients diagnosed annually by 2020, with nearly 700,000 people dying from the disease each year, a media report said on Tuesday.

Researchers from Johns Hopkins University have developed a method to efficiently turn human stem cells into retinal nerve cells that transmit visual signals from the eye to the brain.

Researchers at the Stanford University School of Medicine have identified a gene involved in the control of sleep that, when working properly, appears to reduce the risk of heart failure and improve treatment outcome, says a study.

Researchers have developed a new, more precise way to control the differentiation of stem cells into bone cells which shows promise for bone regeneration, growth and healing.

Pfizer Inc. announced top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.

Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutations, leaving some without access to the most appropriate treatment for them.

U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

[adsense:336x280:8701650588]